Gene clues reveal why some rare leukemia patients resist tagraxofusp therapy

Researchers astatine The University of Texas MD Anderson Cancer Center person identified wherefore immoderate patients with a uncommon benignant of leukemia, called blastic plasmacytoid dendritic compartment neoplasm (BPDCN), yet make absorption to tagraxofusp, the archetypal Food and Drug Administration-approved attraction for this disease.